secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-07-31T12:00:12+00:00
Accession:  0001437749-26-025167
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin reports 37% blinded CRc in MIRACLE trial; venetoclax-failed subgroup similar
--------------------------------------------------------------------------------

- Preliminary blinded CRc of 37% and CR of 24% in 62 evaluable R/R AML subjects.
- Among 30 patients who failed prior venetoclax, CRc also 37% (3x published salvage rate of ~13%).
- No cardiotoxicity observed; enrollment at 74 of 90; final Part A treatment expected Sept 2026.
- Unblinded Part A results expected Dec 2026–Feb 2027; prior unblinded Annamycin arms showed CRc 50-57% vs control 29%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926025167/0001437749-26-025167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926025167/mbrx20260729_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-025167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer